DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo


company name or ticker

An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?

The healthcare gurus known as the Baker Brothers have amassed a huge position in the orphan drugmaker Synageva BioPharma Corp. Should investors follow in their footsteps?

Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog

3 Biotechs Looking Good this Earnings Season - Earnings ESP

Stocks That Battle Cancer Were The Best-Performing Biotechs In January

New Lifetime High Reached By Pharmacyclics (PCYC)

5 Things Johnson & Johnson's Management Wants You to Know

Since earnings reports only scratch the surface of how a company is performing, we decided to take a deeper dive into what Johnson & Johnson's management had to say about its latest quarter. Here are the five most important things you need to know as an investor.

Why You Shouldn't Bet Against Pharmacyclics (PCYC) Stock - Tale of the Tape

Pharmacyclics Has Moderate Upside And A Very Limited Downside

Why Pharmacyclics (PCYC) Could Be Positioned for a Surge? - Tale of the Tape

Can The Uptrend Continue for Pharmacyclics (PCYC)? - Tale of the Tape

See More Articles...